USA – FDA Warns of Potential Cancer Risk With Weight Loss Drug

The US Food and Drug Administration (FDA) on Tuesday alerted the public to the results from a clinical trial that showed a possible increased risk of cancer with Eisai’s weight management drug Belviq (lorcaserin) and the extended release version.

“At this time, the cause of the cancer is uncertain, and we cannot conclude that lorcaserin contributes to the cancer risk. However, we wanted to make the public aware of this potential risk. We are continuing to evaluate the clinical trial results and will communicate our final conclusions and recommendations when we have completed our review,” FDA said.

First approved in 2012, Belviq is intended to help with weight loss for those eating a reduced-calorie diet and increasing exercise…